Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Niagen Bioscience (OCD1) Stock Price & Analysis

OCD1 Stock Chart & Stats

€1.80-€0.04(-2.17%)
At close: 5:30 PM GMT+1
€3€3.5€420 Apr6 May8 May1 Jun
Day’s Range
EUR 1.80 - EUR 1.80
52-Week Range
EUR 1.74 - EUR 6.25
Previous Close
EUR 1.84
Volume
0
Average Volume (3M)
0
Market Cap
EUR 165.08M
Enterprise Value
EUR 198.78M
Total Cash (Recent Filing)
EUR 66.74M
Total Debt (Recent Filing)
EUR 2.33M
Price to Earnings (P/E)
12.0
Beta
0.96
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
0
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Profitability And Margins

Sustained positive operating and net profitability, combined with strong gross margins, indicates the business model can convert branded health products into attractive economics. If maintained, this margin structure supports reinvestment, resilience, and greater earnings power over the next several quarters.

Conservative Balance Sheet

Very low leverage reduces financial risk and gives Niagen flexibility to fund product development, marketing, and strategic initiatives without relying heavily on external capital. Growing equity and improving returns also suggest that recent profitability is strengthening the underlying financial base.

Expanding Growth Platforms

Growth in direct-to-consumer sales alongside the Niagen Plus telehealth launch and pharmaceutical development broadens the company beyond its existing supplement channels. These initiatives could expand customer access, diversify revenue sources, and create longer-term growth opportunities.

Bears Say

Weak Recent Revenue Momentum

Weak or negative trailing revenue growth suggests that demand has softened or prior expansion has normalized, limiting near-term operating leverage. Unless newer channels and products accelerate adoption, slower top-line growth could constrain margin expansion and reduce the pace of earnings improvement.

Inconsistent Cash Conversion

Operating cash flow below net income raises questions about how consistently reported profits convert into usable cash, particularly as the company funds expansion. Earlier cash burn reinforces the need to manage working capital and investment carefully so growth does not weaken financial flexibility.

Profitability Still Lacks A Full-cycle Record

The recent turnaround is encouraging, but substantial losses in earlier years mean the current profit level has not yet been tested across a full business cycle. Elevated investment in 2026 may also pressure results before newer initiatives contribute meaningful, durable returns.

Niagen Bioscience News

OCD1 FAQ

What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was €1.74 and its highest was €6.25 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is €165.08M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 2 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Aug 04, 2026. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of €0.007 by €0.002.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.00.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 79,126,000 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of €0.009 in its last earnings report, beating expectations of €0.007. Following the earnings report the stock price went down -7.801%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Hedge funds hold Niagen Bioscience shares: the largest hedge-fund position in Niagen Bioscience is 1,402,587,130 shares, and hedge funds decreased their holdings by 94.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology